| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20,400 | 20 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 20 Feb 2026 | 1 | $0 | 4 | Director | 23 Feb 2026, 16:21 |
| ANTX | AN2 Therapeutics, Inc. | 22 May 2025 | 1 | $0 | 4 | Director | 23 May 2025, 16:57 |
| ANTX | AN2 Therapeutics, Inc. | 19 Jun 2024 | 1 | $0 | 4 | Director | 21 Jun 2024, 17:58 |
| ANTX | AN2 Therapeutics, Inc. | 07 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 20:37 |
| ANTX | AN2 Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Director | 16 May 2022, 21:18 |
| ANTX | AN2 Therapeutics, Inc. | 24 Mar 2022 | 0 | $0 | 3 | Director | 24 Mar 2022, 21:27 |